The U.S. Food and Drug Administration approved the first generic versions of Eli Lilly & Co.'s Strattera, a drug for the treatment of attention-deficit hyperactivity disorder in children and adults.

The generic atomoxetine will be marketed in multiple doses by Apotex Inc., Teva Pharmaceutical Industries Ltd.'s Teva Pharmaceuticals USA Inc., Aurobindo Pharma Ltd. and Glenmark Pharmaceuticals Ltd.

Eli Lilly reported Strattera sales of $854.7 million for the full year 2016.